Business
SK Capital Partners Announces Agreement to Sell Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG
NEW YORK, January 27, 2026--SK Capital Partners Announces Agreement to Sell Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG
About this update from Siegfried Holding Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/952a9223a721fac4d291a85fcc79cccc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/32H4K5GET9htU1jFBxJqmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/952a9223a721fac4d291a85fcc79cccc","width":480,"height":251}},"lazy":false},{"type":"text","content":"NEW YORK, January 27, 2026--(BUSINESS WIRE)--Affiliates of funds advised by SK Capital Partners, LP ("SK Capital"), a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today they have entered into an agreement to sell Noramco, Extractas Biosciences, and Purisys of the Noramco Group ("Noramco" or the "Company") to Siegfried Holding AG (SIX: SFZN; "Siegfried"), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry.","length":569,"tagName":"p"},{"type":"text","content":"Following the close of the transaction, SK Capital will retain ownership of Halo Pharmaceuticals, a leading finished-dose-form CDMO in the United States and Canada with sterile-fill-finish and controlled substance production capabilities.","length":238,"tagName":"p"},{"type":"text","content":"Aaron Davenport, Chairman of Noramco’s Board of Directors and Managing Director at SK Capital, said, "SK Capital is privileged to have supported the Noramco Group and its team. We are excited to continue to support Halo Pharmaceuticals and accelerate its next phase of growth with greater focus as a standalone platform."","length":331,"tagName":"p"},{"type":"text","content":"Jefferies is acting as Lead Financial Advisor to the Company in connection with the transaction. RBC Capital Markets, LLC and Rothschild & Co. are also serving as financial advisors to the Company.","length":201,"tagName":"p"},{"type":"text","content":"The transaction is subject to customary closing conditions and regulatory approvals.","length":84,"tagName":"p"},{"type":"text","content":"About SK Capital:SK Capital is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sect...